Affinity maturation of antibodies assisted by in silico modeling

Rational engineering methods can be applied with reasonable success to optimize physicochemical characteristics of proteins, in particular, antibodies. Here, we describe a combined CDR3 walking randomization and rational design-based approach to enhance the affinity of the human anti-gastrin TA4 scFv. The application of this methodology to TA4 scFv, displaying only a weak overall affinity for gastrin17 (KD = 6 μM), resulted in a set of nine affinity-matured scFv variants with near-nanomolar affinity (KD = 13.2 nM for scFv TA4.112). First, CDR-H3 and CDR-L3 randomization resulted in three scFvs with an overall affinity improvement of 15- to 35-fold over the parental. Then, the modeling of two scFv constructs selected from the previous step (TA4.11 and TA4.13) was followed by a combination of manual and molecular dynamics-based docking of gastrin17 into the respective binding sites, analysis of apparent packing defects, and selection of residues for mutagenesis through phage display. Nine scFv mutants were obtained from the second maturation step. A final 454-fold improvement in affinity compared with TA4 was obtained. These scFvs showed an enhanced potency to inhibit gastrin-induced proliferation in Colo 320 WT and BxPc3 tumoral cells. In conclusion, we propose a structure-based rational method to accelerate the development of affinity-matured antibody constructs with enhanced potential for therapeutic use.

[1]  D. Altschuh,et al.  Designing antibodies for the inhibition of gastrin activity in tumoral cell lines , 2008, International journal of cancer.

[2]  Marc De Maeyer,et al.  Paratope and Epitope Mapping of the Antithrombotic Antibody 6B4 in Complex with Platelet Glycoprotein Ibα* , 2007, Journal of Biological Chemistry.

[3]  S. Batra,et al.  Engineering antibodies for clinical applications. , 2007, Trends in biotechnology.

[4]  S. Watson,et al.  G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy , 2007, Expert opinion on biological therapy.

[5]  J. Desmet,et al.  Rational humanization of the powerful antithrombotic anti-GPIbα antibody: 6B4 , 2006, Thrombosis and Haemostasis.

[6]  Andreas Plückthun,et al.  Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. , 2006, Journal of molecular biology.

[7]  Leonard G Presta,et al.  Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. , 2006, Advanced drug delivery reviews.

[8]  Rodrigo Barderas,et al.  A fast mutagenesis procedure to recover soluble and functional scFvs containing amber stop codons from synthetic and semisynthetic antibody libraries. , 2006, Journal of immunological methods.

[9]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[10]  Woody Sherman,et al.  Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design , 2006, Protein science : a publication of the Protein Society.

[11]  Leonard G Presta,et al.  Selection, design, and engineering of therapeutic antibodies. , 2005, The Journal of allergy and clinical immunology.

[12]  J. Casal,et al.  Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation , 2005, Clinical Cancer Research.

[13]  Guido Cappuccilli,et al.  A general method for greatly improving the affinity of antibodies by using combinatorial libraries. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[15]  Mitchell Ho,et al.  In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin* , 2005, Journal of Biological Chemistry.

[16]  Andreas Plückthun,et al.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.

[17]  S. Watson,et al.  A phase II study of G17DT in gastric carcinoma. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  Ana Cauerhff,et al.  Structural mechanism for affinity maturation of an anti-lysozyme antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Paul W. H. I. Parren,et al.  Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.

[20]  Kristiina Takkinen,et al.  Crystal Structure of an in Vitro Affinity- and Specificity-matured Anti-testosterone Fab in Complex with Testosterone , 2002, The Journal of Biological Chemistry.

[21]  R. Pounder,et al.  Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Lasters,et al.  Fast and accurate side‐chain topology and energy refinement (FASTER) as a new method for protein structure optimization , 2002, Proteins.

[23]  Trisha Gura,et al.  Therapeutic antibodies: Magic bullets hit the target , 2002, Nature.

[24]  I. Tomlinson,et al.  Selection of large diversities of antiidiotypic antibody fragments by phage display. , 2002, Journal of molecular biology.

[25]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[26]  S. Watson,et al.  Expression of gastrin in developing gastric adenocarcinoma , 2001, The British journal of surgery.

[27]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[28]  S. Watson,et al.  Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. Rehfeld,et al.  Closing the gastrin loop in pancreatic carcinoma , 2000, Cancer.

[30]  G. Adams,et al.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.

[31]  E L Sonnhammer,et al.  The imprint of somatic hypermutation on the repertoire of human germline V genes. , 1996, Journal of molecular biology.

[32]  D R Burton,et al.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. , 1995, Journal of molecular biology.

[33]  C. Seva,et al.  Growth-promoting effects of glycine-extended progastrin. , 1994, Science.

[34]  D R Burton,et al.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Koski,et al.  Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. , 1993, Cancer research.

[36]  R. Ladner,et al.  Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13. , 1991, Gene.

[37]  Shoshana J. Wodak,et al.  Interactive computer animation of macromolecules , 1984 .

[38]  J. Desmet,et al.  Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. , 2006, Thrombosis and haemostasis.

[39]  J. Larrick,et al.  Identification of functional and structural amino-acid residues by parsimonious mutagenesis. , 1996, Gene.

[40]  J. P. Smith,et al.  Identification of gastrin as a growth peptide in human pancreatic cancer. , 1995, The American journal of physiology.

[41]  J. M. Carter,et al.  Epitope mapping of a protein using the Geysen (PEPSCAN) procedure. , 1994, Methods in molecular biology.

[42]  D. Webster,et al.  Antibody-antigen interactions , 1994 .

[43]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[44]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.